Tyra Biosciences (TYRA) risk factors
Item 1A of every Tyra Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors100 risks8 new6 dropped17 reworded
Tyra Biosciences added risks covering broader biopharmaceutical uncertainties, EU IVDR compliance for companion diagnostics, and accelerated approval pathways. The company dropped specific references to 2027 cash runway estimates and FDA inspection postponements.
Filed Mar 02, 2026 - FY2024 10-K risk factors98 risks
Clinical stage biopharmaceutical company with no approved products focused on developing novel precision therapies using the SNÅP platform. Relies heavily on third-party manufacturers, clinical trial sites, and companion diagnostic partners. Faces substantial ongoing capital requirements with cash runway projected through at least 2027.
Filed Mar 27, 2025